COMPANY NEWS (sm) provided by Dow Jones/News Retrieval
Copyright (c)1997 Dow Jones & Company

6/26/97 Hemispherx Biopharma Says 5 Sites Get OK For Ampligen Trial

PHILADELPHIA (Dow Jones)--Hemispherx Biopharma Inc. (HEMX) said five 
clinical sites received approval to take part in a protocol using its 
Ampligen drug to treat patients with chronic fatigue syndrome. 
  In a press release, Hemispherx said the Food and Drug 
Administration has approved cost recovery for the protocol, meaning 
patients reimburse the company for the cost of the drug.

  The drug costs $2,100 for the first eight weeks of treatment and $2,
400 for each eight weeks thereafter. 
  Hemispherx is developing Ampligen for possible restoration of 
physical and cognitive functions of patients with chronic fatigue 
syndrome, estimated to afflict 500,000 to 2 million people in the U.S.
 
  Hemispherx is a biopharmaceutical company. 
  (END) DOW JONES NEWS 06-26-97
   8:33 AM